Monoclonal antibody reduces Cdiff recurrence

In this trial of 200 patients with active Cdiff infection, they were randomized to placebo or a single IV infusion of a monoclonal antibody against toxin A and B, in addition to standard treatment with either metronidazole or vancomycin. Those in the antibody group had lower risk of recurrence at 84 days (7% vs 25%) with no difference in adverse events. A single infusion of monoclonal antibody significantly reduces the risk of recurrent Cdiff infection (abstract).

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment